 Bispecific antibodies that direct T cells to tumor cells, by simultaneously binding CD3 on T cells and a target on tumor cells, have the potential to drive tumor cell killing. This collaboration will leverage Xencors XmAb engineering platform to design and manufacture CD3 bispecific antibodies and Atrecas ability to generate novel antibody-target pairs through its discovery platform, including its Immune Repertoire Capture IRCTM technology. 